Tissue plasminogen activator has, over the years, been widely accepted to be the safer thrombolytic drug for myocardial infarction and stroke, but recent stroke studies and trials with tPA suggest that this agent adversely affects the integrity of the blood-brain barrier if given after a small (3–4 h) “window of opportunity.” Studies also suggest that if administration of activated Protein C is combined with tPA therapy then it reduces chances of hemorrhage during therapy in strokes [50]. Here, PLAT is linked to myocardial infarction.